References

The following are referenced in this project:

  • Adams, C.P. and Brantner, V.V. (2006) Estimating The Cost Of New Drug Develop-ment: Is It Really $802 Million? Health Affairs, 25:420-428.
  • ADIS R&D Insight. (2010) World Wide Web URL: http://bi.adisinsight.com/rdi/viewdocument.aspx?render=view&mode=remote&adnm=800004827&PushValidation=121745.
  • Ashburn, T. and Thor, K. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3:673-683.
  • Bader, G.D. and Hogue, C.W.V. (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4:2.
  • Berenson, A. (2005) Sales of impotence drugs fall, defying expectations. New York Times, December 4, 1.
  • Boshier, A., Wilton, L.V. and Shakir, S.A.W. (2003) Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general prac-tice use in England in 2000. European Journal of Clinical Pharmacology, 59(10):767-773.
  • Breitkreutz, B., Stark, C. and Tyers, M.(2003) Osprey: a network visualization sys-tem, Genome Biology, 4:R22.
  • Carter, A., Merchav, S., Silvian-Draxler, I. and Tatarsky, I. (1989) The role of inter-leukin-1 and tumour necrosis factor-a in human multiple myeloma. British Jour-nal of Haematology, 74(4):424-431.
  • Chan, C.S., Guzman, J.N., Ilijic, E., Mercer, J.N., Rick, C., Tkatch, T., Meredith, G.E. and Surmeier, D.J. (2007) `Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature, 447:1081-1086.
  • Cockell, S.J., Weile, J., Lord, P., Wipat, C., Andriychenko, D., Pocock, M., Wilkin-son, D., Young, M. and Wipat, A. (2010) An integrated dataset for in silico drug discovery. Journal of Integrative Bioinformatics, 7(3):116.
  • Cline, M.S., Smoot, M., Cerami, E., et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nature Protocols, 2:2366-2382.
  • Davis, A.P., Murphy, C.G., Saraceni-Richards, C.A., Rosenstein, M.C., Wiegers, T.C. and Mattingly, C.J. (2009) Comparative Toxicogenomics Database: a knowledge-base and discovery tool for chemical–gene–disease networks. Nucleic Acids Res., 37:D786-792.
  • DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22:151-185.
  • DiMasi, J.A., Feldman, L., Seckler, A. and Wilson, A. (2010) Trends in Risks Associ-ated With New Drug Development: Success Rates for Investigational Drugs. Clinical Pharmacology & Therapeutics, 87(3):272–277.
  • Dimond, P.F. (2010) Drug Repositioning Gains in Popularity. Genetic Engineering and Biotechnology News, 30(8).
  • Dudley, J.T., Schadt, E., Sirota, M., Butte, A.J. and Ashley, E. (2010) Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks. Journal of car-diovascular translational research, accepted.
  • Ganz, M., Mokabberi, R. and Sica, D.A. (2007) Comparison of Blood Pressure Con-trol With Amlodipine and Controlled-Release Isradipine: An Open-Label, Drug Substitution Study. The Journal of Clinical Hypertension, 7(4):27-31.
  • Girault, J-A. and Greengard, P. (2004) The Neurobiology of Dopamine Signaling. Archives of Neurology, 61:641-644.
  • Goldstein, I., Lue, T.F., Padma-Nathan, H., Rosen, R.C., Steers, W.D. and Wicker P.A. (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. The New England Journal of Medicine, 338:1397-1404.
  • Gosling, J., Joy, B., Steele, G. and Bracha, G. (2005) The Java language specification, third edition. Addison-Wesley.
  • Greenberg, D.A. (1999) Neuromuscular disease and calcium channels. Muscle nerve, 22:1341-1349.
  • Handler, C.E., Rosenthala, E., Tsagadopoulosa, D. and Najma, Y. (1988) Comparison of isradipine and nifedipine in chronic stable angina. International Journal of Cardiology, 18(1):15-26.
  • Harris, C.R., Gualtieri, J., Stark, G. (1997) Fatal bupropion overdose. Journal of Toxicology: Clinical Toxicology, 35(3):321–324.
  • Informa. (2010) Pharma R&D Annual Review. Pharmaprojects – Pharmaceutical Research & Development Pipeline Intelligence, World Wide Web URL: http://www.pharmaprojects.com/therapy_analysis/annual-review-2010.htm.
  • Itzkovitz, S. and Alon, U. (2005) Subgraphs and network motifs in geometric net-works. Physical Review, 71(2).
  • Kashtan, N., Itzkovitz, S., Milo, R. and Alon, U. (2002) Mfinder tool guide. Technical report, Department of Molecular Cell Biology and Computer Science and Applied Mathematics, Weizman Institute of Science, Israel.
  • Keith, A. (2000) The Economics of Viagra. Viagra Economics, 19(2):147-157.
  • Konagurthu, A.S. and Lesk, A.M. (2008) On the origin of distrubtion patterns of motifs in biological networks. BMC Systems Biology, 2:73.
  • Köhler, J., Baumbach, J., Taubert, J., Specht, M., Skusa, A., Ruegg, A., Rawlings, C., Verrier, P., and Philippi, S. (2006) Graph-based analysis and visualization of ex-perimental results with ONDEX. Bioinformatics, 22:1383-1390.
  • Loughlin, K. and Generali, J. (2006) The Guide to Off-Label Prescription Drugs: New Uses for FDA-Approved Prescription Drugs. Free Press, New York, USA.
  • Lui, R.H., Smith, M.K., Basta, S.A. and Farmer, E.R. (2006) Azelaic Acid in the treatment of Papulopustular Rosacea. Archives of Dermatology, 142:1047-1052.
  • Martin, Y.C., Kafron, J.L. and Traphagen, L.M. (2002) Do structurally similar mole-cules have similar biological activity? J. Med. Chem., 45:4350-4358.
  • Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D. and Alon, U. (2002) Network Motifs: Simple Building Blocks of Complex Networks. Science, 298(5594):824-827.
  • Modell, J.G., Rosenthal, N.E., Harriet, A.E., Krihen, A., Asgharian, A., Foster, V.J., Metz, A., Rockett, C.B. and Wightman, D.S. (2005) Seasonal Affective Disorder and its Prevetion by Anticipatory Treatment with Bupropion XL. Biological Psychiatry, 58(8):658-667.
  • Moyer, J.H., Kent, B., Knight, R., Morris, G., Huggins, R. and Handley C.A. (1954) Laboratory and Clinical Observations on Chlorpromazine. American Journal of the Medical Sciences, 227(3):283-290.
  • O’Connor, K.A. and Roth, B.L. (2005) Finding New Tricks for Old Drugs: An Effi-cient Route for Public-Sector Drug Discovery. Nature Reviews Drug Discovery, 4:1005-1014.
  • O’Hagan, P. and Farkas, C. (2009) Bringing pharma R&D back to health. Bain & Company, Inc.
  • Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 9th August 2010. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/.
  • Özyazgan, S., Senses, V., Utkan, T., Yildiran, G., Ulak, G., Gacar, N., Özüner, Z. and Akkan, A.G. The Effect of Isradipine on Maximal Electroshock Seizures in Mice. General Pharmacology, 31(1):133-135.
  • Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R. and Schacht, A.L. (2010) How to improve R&D productivity: the pharma-ceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9:203-214.
  • Pfizer (2010) Pfizer, Washington University Announce Groundbreaking Collabora-tion. Pfizer Press Release, 17/05/2010.
  • Rivera, C.G., Vakil, R. and Bader, J.S. (2010) NeMo: Network Module identification in Cytoscape. BMC Bioinformatics, 11:S61.
  • Scheid, C.R., Honeyman, T.W. and Fay, F.S. (1979) Mechanism of beta-adrenergic relaxation of smooth muscle. Nature, 277(5691):32-36.
  • Schreiber, F. and Schwöbbermeyer, H. (2005) Mavisto: a tool for the exploration of network motifs. Bioinformatics, 21:3572–3574.
  • Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B. and Ideker, T. (2003) Cytoscape: a software environment for in-tegrated models of biomolecular interaction networks. Genome Research, 13(11):2498-2504.
  • Shen-Orr, S.S., Milo, R., Mangan, S. and Alon, U. (2002) Network motifs in the transcriptional regulation network of Escherichia coli. Nature Genetics, 31:64-68.
  • Strauss, S. (2010) Pharma embraces open source models. Nature biotechnology, 28(7):631-634.
  • Taubert, J., Sieren, K.P., Hindle, M., Hoekman, B., Winnenburg, R., Philippi, S., Rawlings, C. and Köhler, J. (2007) The OXL format for the exchange of inte-grated datasets. Journal of Integrative Bioinformatics, 4(3):62.
  • Tseng, S., Pak, G., Washenik, K., Pomeranz, M.K. and Shupack J.L. (1996) Redis-covering thalidomide: A review of its mechanism of action, side effects, and po-tential uses. Journal of the American Academy of Dermatology, 35(6):969-979.
  • Vargas, G., Boutouyrie, B., Ostrowitzki, S. and Santarelli, L. (2010) Arguments Against Precompetive Collaboration. Clinical Pharmacology & Therapeutics, 87(5):527-529.
  • Wernicke, S. and Rasche, F. (2006) FANMOD: a tool for fast network motif detec-tion. Bioinformatics, 22(9):1152-1153.
  • Wernicke, S. (2006) Efficient Detection of Network Motifs. Transactions on Computational Biology and Bioinformatics, 3(4):347-359.
  • Whitten, L. (1996) Bupropion Helps People With Schizophrenia Quit Smoking. National Institute on Drug Abuse. Drug Findings, 20(5).
  • Wishart, D.S., Knox, C., Guo, A.C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., Hassanali, M. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 36:D901-906.
  • Wuchty, S., Oltvai, Z.N. and Barabási, A-L. (2003) Evolutionary conservation of motif constituents in the yeast protein interaction network. Nature Genetics, 35:176-179.